Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F16%3A10333077" target="_blank" >RIV/00216208:11110/16:10333077 - isvavai.cz</a>
Alternative codes found
RIV/00023728:_____/16:N0000026
Result on the web
<a href="http://dx.doi.org/10.2106/JBJS.15.01217" target="_blank" >http://dx.doi.org/10.2106/JBJS.15.01217</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2106/JBJS.15.01217" target="_blank" >10.2106/JBJS.15.01217</a>

Result language
angličtina
Original language name
Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks
Original language description
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis. The teriparatide group completed the TUG test in a shorter time at 6, 12, 18, and 26 weeks. They also reported less pain on a visual analog scale immediately after the TUG test at 12 and 18 weeks. Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)